In our research, we exploit this requirement to specifically target the BRCA1 or BRCA2-defective cancer cells with inhibitors of PARP. This treatment is unlikely to cause many side effects; prolonged treatments with PARP inhibitors are well tolerated in mice.
在我们的研究中，我们探寻了使用PARP抑制剂的必备条件，尤其针对具有BRCA1或BRCA2缺陷的癌细胞。该治疗方法不会引起诸多副作用；老鼠对PARP抑制剂的长期治疗表现出良好的耐受性。